-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NC-2400 in Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NC-2400 in Dyslipidemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NC-2400 in Dyslipidemia Drug Details: NC-2400 (CER-002) is under development for the treatment...
-
Product Insights
Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Uveitis - Drugs In Development, 2023’, provides an overview of the Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Atherosclerosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Atherosclerosis - Drugs In Development, 2023’, provides an overview of the Atherosclerosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atherosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Arteriosclerosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Arteriosclerosis - Drugs In Development, 2023’, provides an overview of the Arteriosclerosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arteriosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs In Development, 2023’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sepsis - Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NC-2400
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NC-2400 Drug Details NC-2400 (CER-002) is under development for the treatment of dyslipidemia with...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CER-209
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CER-209 Drug Details CER-209 is under development for the treatment of dyslipidemia with low...
-
Product Insights
Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Atherosclerosis (or arteriosclerotic vascular disease) may occur with symptoms including chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation. The Atherosclerosis pipeline drugs market research report outlays comprehensive information on the Atherosclerosis targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA)...